Brief: Coloplast Keeps EBIT Margin Guidance Unchanged

Coloplast A/S

07/05/2024 06:16

May 7 (Reuters) - Coloplast A/S  COLOb.CO :
    * ATOS MEDICAL AND KERECIS  DELIVER DOUBLE-DIGIT GROWTH IN Q2
    * FY 2023/24 ORGANIC GROWTH AND REPORTED EBIT MARGIN GUIDANCE UNCHANGED
    * GUIDANCE FOR REPORTED REVENUE GROWTH ADJUSTED TO 10-11%
    * PREVIOUS REPORTED REVENUE GROWTH GUIDANCE: AROUND 11%
    * KERECIS IS CONSIDERED TO NOT MEET CLINICAL QUALIFICATION INTRODUCED IN LCD DRAFT POLICY
AND IS
NOT INCLUDED ON COVERED LIST

Source text for Eikon:  ID:nGNEbvbdq9 
Further company coverage:  COLOb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))